DK0656778T3 - Enantiomert rene beta-D-dioxolannukleosider - Google Patents

Enantiomert rene beta-D-dioxolannukleosider

Info

Publication number
DK0656778T3
DK0656778T3 DK93920366T DK93920366T DK0656778T3 DK 0656778 T3 DK0656778 T3 DK 0656778T3 DK 93920366 T DK93920366 T DK 93920366T DK 93920366 T DK93920366 T DK 93920366T DK 0656778 T3 DK0656778 T3 DK 0656778T3
Authority
DK
Denmark
Prior art keywords
enantiomerically pure
pure beta
dioxolane nucleosides
image
pharmaceutically acceptable
Prior art date
Application number
DK93920366T
Other languages
Danish (da)
English (en)
Inventor
Raymond F Schinazi
Chung K Chu
Original Assignee
Univ Emory
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25467279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0656778(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory, Univ Georgia Res Found filed Critical Univ Emory
Application granted granted Critical
Publication of DK0656778T3 publication Critical patent/DK0656778T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK93920366T 1992-08-25 1993-08-25 Enantiomert rene beta-D-dioxolannukleosider DK0656778T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/935,515 US5925643A (en) 1990-12-05 1992-08-25 Enantiomerically pure β-D-dioxolane-nucleosides
PCT/US1993/008044 WO1994004154A1 (fr) 1992-08-25 1993-08-25 NUCLEOSIDES ENANTIOMERIQUEMENT PURS DE β-D-DIOXOLANE

Publications (1)

Publication Number Publication Date
DK0656778T3 true DK0656778T3 (da) 2001-07-30

Family

ID=25467279

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93920366T DK0656778T3 (da) 1992-08-25 1993-08-25 Enantiomert rene beta-D-dioxolannukleosider

Country Status (12)

Country Link
US (2) US5925643A (fr)
EP (2) EP1081148B1 (fr)
JP (3) JP3519736B2 (fr)
AT (2) ATE498624T1 (fr)
AU (1) AU670637C (fr)
CA (1) CA2143107C (fr)
DE (2) DE69334348D1 (fr)
DK (1) DK0656778T3 (fr)
ES (1) ES2157929T3 (fr)
GR (1) GR3036393T3 (fr)
PT (1) PT656778E (fr)
WO (1) WO1994004154A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
JP4413996B2 (ja) 1995-06-07 2010-02-10 エモリー・ユニバーシティ 抗ｂ型肝炎ウィルス活性を有するヌクレオシド
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
ES2221164T3 (es) 1997-03-19 2004-12-16 Emory University Sintesis y actividad de la inmunodeficiencia humana y antivirus de la hepatitis b de nucleosidos de 1,3-oxaselenolano.
DE19739827B4 (de) * 1997-09-11 2007-05-10 Robert Bosch Gmbh Verfahren und Vorrichtung zur Steuerung einer Betriebsgröße eines Kraftfahrzeugs
DE69942042D1 (de) 1998-11-02 2010-04-01 Gilead Sciences Inc Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
NZ513094A (en) * 1998-12-23 2004-05-28 Shire Biochem Inc Antiviral nucleoside analogues
US6511983B1 (en) 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
WO2001032153A2 (fr) 1999-11-04 2001-05-10 Shire Biochem Inc. Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides
WO2002031176A1 (fr) * 2000-10-12 2002-04-18 Mitsui Chemicals, Inc. Procédé permettant la production de nucléosides
PT1574512E (pt) 2001-03-01 2008-03-05 Abbott Lab Formas polimórficas e outras formas cristalinas de cis-ftc
ES2360096T3 (es) * 2002-08-06 2011-05-31 Pharmasset, Inc. Procedimientos de preparación de nucleosidos de 1,3-dioxolano.
EP1608629A1 (fr) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinones en tant qu inhibiteurs de transcriptase inverse
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
CN105039489A (zh) * 2004-02-03 2015-11-11 埃莫里大学 制备1,3-二氧戊环核苷的方法
US7446234B2 (en) * 2005-09-27 2008-11-04 Council Of Scientific And Industrial Research Bisphenol compound and process for preparation thereof
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
JP5216768B2 (ja) 2006-08-16 2013-06-19 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤
EP2089384B1 (fr) 2006-12-13 2015-08-05 F. Hoffmann-La Roche AG Inhibiteurs non nucléosidiques de la transcriptase inverse
EP2155692B1 (fr) 2007-05-30 2015-06-17 F. Hoffmann-La Roche AG Inhibiteurs non nucléosidiques de transcriptase inverse
WO2009080534A1 (fr) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Composés hétérocycliques antiviraux
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
WO2011077100A1 (fr) 2009-12-24 2011-06-30 Cipla Limited Composition antirétrovirale
UA122959C2 (uk) 2010-03-31 2021-01-27 Гайлід Фармассет Елелсі Нуклеозидфосфорамідати

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE3689976T2 (de) * 1985-05-15 1995-03-16 Wellcome Found Therapeutische Nucleoside und deren Herstellung.
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) * 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
WO1992010496A1 (fr) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. NUCLEOSIDES DE β-L-(-)-1,3-OXATHIOLANE ENANTIOMERIQUEMENT PURS
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
BR9107214A (pt) 1990-12-14 1993-11-16 Henkel Corp Composicao liquida aquosa de materia,composicao concentrada liquida aquosa de materia,e,processo para a limpeza de uma superficie plastica suja
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ATE361293T1 (de) * 1991-03-06 2007-05-15 Univ Emory Salze und amide von (-) cis 5-fluoro-2'-deoxy-3'- thiacytidine geeignet für die behandlung von hepatitis b
WO1992018517A1 (fr) * 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
EP0656778A1 (fr) 1995-06-14
CA2143107A1 (fr) 1994-03-03
EP1081148A2 (fr) 2001-03-07
GR3036393T3 (en) 2001-11-30
JP3519736B2 (ja) 2004-04-19
EP0656778A4 (fr) 1995-08-02
JP4503206B2 (ja) 2010-07-14
JP2004149543A (ja) 2004-05-27
ATE201599T1 (de) 2001-06-15
EP1081148B1 (fr) 2011-02-16
US5767122A (en) 1998-06-16
DE69334348D1 (de) 2011-03-31
DE69330274D1 (de) 2001-07-05
EP0656778B1 (fr) 2001-05-30
AU5093393A (en) 1994-03-15
EP1081148A3 (fr) 2003-03-05
CA2143107C (fr) 2004-11-23
JP2002114787A (ja) 2002-04-16
ATE498624T1 (de) 2011-03-15
AU670637B2 (en) 1996-07-25
ES2157929T3 (es) 2001-09-01
DE69330274T2 (de) 2001-11-15
AU670637C (en) 2002-07-25
WO1994004154A1 (fr) 1994-03-03
US5925643A (en) 1999-07-20
PT656778E (pt) 2001-09-28
JPH08501086A (ja) 1996-02-06

Similar Documents

Publication Publication Date Title
DK0656778T3 (da) Enantiomert rene beta-D-dioxolannukleosider
DK0666749T3 (da) Enantiomert rene beta-D-dioxalannukleosider med selektiv antihepatitis B virus aktivitet
AU1787492A (en) Antiviral combinations containing nucleoside analogs
CA2171550A1 (fr) Nucleosides avec activite virale anti-hepatite b
IL99755A0 (en) Hydroxymethyl(methylenecyclopentyl)purines and pyrimidines and pharmaceutical compositions containing the same
CY2047B1 (en) Use of 1,3-oxathiolane nucleoside analogues in the manufacture of a medicament for treatment of hepatitis B
ES2124257T3 (es) Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores.
HK1014660A1 (en) 3'-Azido-2',3'-dideoxy-5- methylcytidine anti-viral composition
HUT53522A (en) Process for producing pharmaceutical compositions comprising purine derivatives
ATE237619T1 (de) Sesquiterpen-derivate mit antiviraler aktivität
ZA898926B (en) Antiviral compounds
PT728002E (pt) Utilizacao de derivados de 2-amino purina para o tratamento e profilaxia da infeccao pelo virus de herpes 7 humano
ES8308335A1 (es) Un procedimiento para la preparacion de nuevos derivados de desoxiuridina.
ZA948907B (en) Use of 2-amino purine derivatives for the treatment and pro-phylaxis of human herpes virus 6 infections